Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
AZoLifeSciences on MSN

New Cloaked CRISPR Technology Reveals Hidden Gene Targets for Cancer Metastasis

The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible – ...
The Malaysian Reserve

ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery ...
The Manila Times

GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technologyPursues a 'once-and-done' treatment paradigm for diseases with ...

Research challenges idea that gene PTPN22 boosts production of interferons

A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...
The Globe and Mail

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...

Stop through SPOP: Researchers develop strategy against aggressive blood cancer

When blood cancer in children progresses particularly aggressively, it is often due to a genetic defect: a gene fusion, such ...